Skip to main content


Page 33 of 33

  1. While Alzheimer's disease researchers continue to debate the underlying cause(s) of the disease, most agree that a diverse, multi-target approach to treatment will be necessary. To this end, the Alzheimer's Dr...

    Authors: Linda H Lee, Diana W Shineman and Howard M Fillit
    Citation: Alzheimer's Research & Therapy 2010 2:33
  2. In a slowly progressive disorder like Alzheimer disease, evaluation of the clinical effect of novel drug candidates requires large numbers of patients and extended treatment periods. Current cell- and animal-b...

    Authors: Henrik Zetterberg, Niklas Mattsson, Kaj Blennow and Bob Olsson
    Citation: Alzheimer's Research & Therapy 2010 2:32
  3. There is a great need for quick tests that identify treatment response in Alzheimer's disease (AD) to determine who benefits from the treatment. In this study, A Quick Test of cognitive speed (AQT) was compare...

    Authors: Sebastian Palmqvist, Lennart Minthon, Carina Wattmo, Elisabet Londos and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2010 2:29
  4. With the advent of advances in biomarker detection and neuropsychological measurement, prospects have improved for identifying and tracking the progression of Alzheimer's disease (AD) from its earliest stages ...

    Authors: Larry G Brooks and David A Loewenstein
    Citation: Alzheimer's Research & Therapy 2010 2:28
  5. Structural brain deficits have been repeatedly linked to body mass index and obesity, which itself is controlled by the effects of a number of independent genetic loci. One of the most consistently replicated ...

    Authors: Lars Bertram and Hauke Heekeren
    Citation: Alzheimers Res Ther 2010 2:27
  6. Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this s...

    Authors: Roy W Jones
    Citation: Alzheimer's Research & Therapy 2010 2:25
  7. Atrophy measured on structural magnetic resonance imaging (sMRI) is a powerful biomarker of the stage and intensity of the neurodegenerative aspect of Alzheimer's disease (AD) pathology. In this review, we wil...

    Authors: Prashanthi Vemuri and Clifford R Jack Jr
    Citation: Alzheimer's Research & Therapy 2010 2:23
  8. The present review of Alzheimer's disease (AD) rating scales aims to outline the need for a new rating scale to be used in routine clinical practice for long-term medical care of AD patients. An ideal scale would...

    Authors: Philippe Robert, Steven Ferris, Serge Gauthier, Ralf Ihl, Bengt Winblad and Frank Tennigkeit
    Citation: Alzheimer's Research & Therapy 2010 2:24
  9. Since the reformulation of the amyloid cascade hypothesis to focus on oligomeric aggregates of amyloid beta as the prime toxic species causing Alzheimer's disease, many researchers refocused on detecting a spe...

    Authors: Kerensa Broersen, Frederic Rousseau and Joost Schymkowitz
    Citation: Alzheimer's Research & Therapy 2010 2:12
  10. Recently, it has become clear that head trauma can lead to a progressive neurodegeneration known as chronic traumatic encephalopathy. Although the medical literature also implicates head trauma as a risk facto...

    Authors: Brandon E Gavett, Robert A Stern, Robert C Cantu, Christopher J Nowinski and Ann C McKee
    Citation: Alzheimer's Research & Therapy 2010 2:18
  11. Recent advances in biomarkers for Alzheimer's disease (AD) now allow the visualization of one of the hallmark pathologies of AD in vivo, and combination biomarker profiles can now approximate the diagnostic accur...

    Authors: Reisa Sperling and Keith Johnson
    Citation: Alzheimer's Research & Therapy 2010 2:17
  12. Matrix metalloproteinases (MMP) are believed to be involved in the pathologic processes behind Alzheimer's disease (AD). In this study, we aimed to examine the cerebrospinal fluid (CSF) levels of MMPs and tiss...

    Authors: Erik Stomrud, Maria Björkqvist, Sabina Janciauskiene, Lennart Minthon and Oskar Hansson
    Citation: Alzheimer's Research & Therapy 2010 2:20
  13. Evidence from clinical samples and geographically limited population studies suggests that vascular health, diabetes and apolipoprotein ε4 (APOE) are associated with dementia.

    Authors: David J Llewellyn, Iain A Lang, Fiona E Matthews, Brenda L Plassman, Mary AM Rogers, Lewis B Morgenstern, Gwenith G Fisher, Mohammed U Kabeto and Kenneth M Langa
    Citation: Alzheimer's Research & Therapy 2010 2:19
  14. The amyloid hypothesis provides a basis for the development of new therapeutic strategies in Alzheimer's disease. Two large trials have recently been published. The first is a phase 2 study of passive immunoth...

    Authors: Niels D Prins, Pieter Jelle Visser and Philip Scheltens
    Citation: Alzheimer's Research & Therapy 2010 2:5
  15. LY450139 (semagacestat) inhibits γ-secretase, a key enzyme for generation of amyloid β (Aβ), the peptide deposited in plaques in Alzheimer disease (AD). Previous data have shown that LY450139 lowers plasma Aβ,...

    Authors: Erik Portelius, Robert A Dean, Mikael K Gustavsson, Ulf Andreasson, Henrik Zetterberg, Eric Siemers and Kaj Blennow
    Citation: Alzheimer's Research & Therapy 2010 2:7
  16. Since the 1990s, the genetics of Alzheimer disease (AD) has been an active area of research. The identification of deterministic mutations in the APP, PSEN1, and PSEN2 genes responsible for early-onset autosomal ...

    Authors: Nilüfer Ertekin-Taner
    Citation: Alzheimer's Research & Therapy 2010 2:3
  17. Clinicians need to predict prognosis of Alzheimer's disease (AD), and researchers need models of progression to develop biomarkers and clinical trials designs. We tested a calculated initial progression rate t...

    Authors: Rachelle S Doody, Valory Pavlik, Paul Massman, Susan Rountree, Eveleen Darby and Wenyaw Chan
    Citation: Alzheimer's Research & Therapy 2010 2:2

    The Erratum to this article has been published in Alzheimer's Research & Therapy 2010 2:14

  18. There are no empiric data to support guidelines for duration of therapy with antidementia drugs. This study examined whether persistent use of antidementia drugs slows clinical progression of Alzheimer disease...

    Authors: Susan D Rountree, Wenyaw Chan, Valory N Pavlik, Eveleen J Darby, Samina Siddiqui and Rachelle S Doody
    Citation: Alzheimers Res Ther 2009 1:7
  19. Amyloid is deposited in the walls of arteries and capillaries as cerebral amyloid angiopathy (CAA) in the brains of older individuals and of those with Alzheimer disease (AD). CAA in AD reflects an age-related...

    Authors: Roy O Weller, Stephen D Preston, Malavika Subash and Roxana O Carare
    Citation: Alzheimer's Research & Therapy 2009 1:6
  20. Identifying the causes of dementia is important in the search for effective preventative and treatment strategies. The concept of mild cognitive impairment (MCI), as prodromal dementia, has been useful but rem...

    Authors: Blossom CM Stephan, Fiona E Matthews, Kay-Tee Khaw, Carole Dufouil and Carol Brayne
    Citation: Alzheimers Res Ther 2009 1:4